Vascular Disruptive Hydrogel Platform for Enhanced Chemotherapy and Anti-Angiogenesis through Alleviation of Immune Surveillance
出版年份 2022 全文链接
标题
Vascular Disruptive Hydrogel Platform for Enhanced Chemotherapy and Anti-Angiogenesis through Alleviation of Immune Surveillance
作者
关键词
-
出版物
Pharmaceutics
Volume 14, Issue 9, Pages 1809
出版商
MDPI AG
发表日期
2022-08-30
DOI
10.3390/pharmaceutics14091809
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy
- (2022) Albert Yu et al. Biosensors-Basel
- Interference With Redox Homeostasis Through a G6PD-Targeting Self-Assembled Hydrogel for the Enhancement of Sonodynamic Therapy in Breast Cancer
- (2022) Cuiqing Huang et al. Frontiers in Chemistry
- PEIGel: A biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy
- (2022) Zeyu Xiao et al. Materials Today Bio
- Intratumoral heterogeneity in cancer progression and response to immunotherapy
- (2021) Ilio Vitale et al. NATURE MEDICINE
- Sustained Release Systems for Delivery of Therapeutic Peptide/Protein
- (2021) Tianqi Nie et al. BIOMACROMOLECULES
- Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune‐Based Combination Therapy
- (2021) Hongyu Ma et al. MACROMOLECULAR BIOSCIENCE
- The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors
- (2021) Alina Drzyzga et al. Cancers
- Injectable hydrogel loaded with paclitaxel and epirubicin to prevent postoperative recurrence and metastasis of breast cancer
- (2021) QingQing Leng et al. Materials Science & Engineering C-Materials for Biological Applications
- Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis
- (2021) Bin Zheng et al. Bioactive Materials
- A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
- (2021) Duo Wang et al. Bioactive Materials
- Cancer immunotherapy: Pros, cons and beyond
- (2020) Shuzhen Tan et al. BIOMEDICINE & PHARMACOTHERAPY
- Injectable Anti-inflammatory Nanofiber Hydrogel to Achieve Systemic Immunotherapy Post Local Administration
- (2020) Muchao Chen et al. NANO LETTERS
- TGFβ biology in cancer progression and immunotherapy
- (2020) Rik Derynck et al. Nature Reviews Clinical Oncology
- Recent Advances in Injectable Hydrogels for Controlled and Local Drug Delivery
- (2020) Fabio Rizzo et al. Advanced Healthcare Materials
- Vascular disrupting agents in cancer therapy
- (2020) Ryszard Smolarczyk et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis
- (2020) Sophia Heinrich et al. JOURNAL OF HEPATOLOGY
- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy
- (2019) Thiago A. Patente et al. Frontiers in Immunology
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Targeting Treg cells in cancer immunotherapy
- (2019) Atsushi Tanaka et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
- (2019) Jason H. Gill et al. PHARMACOLOGY & THERAPEUTICS
- Smart Injectable Hydrogels for Cancer Immunotherapy
- (2019) Yu Chao et al. ADVANCED FUNCTIONAL MATERIALS
- Nanogel-Incorporated Injectable Hydrogel for Synergistic Therapy Based on Sequential Local Delivery of Combretastatin-A4 Phosphate (CA4P) and Doxorubicin (DOX)
- (2018) Wen Jing Yang et al. ACS Applied Materials & Interfaces
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Tumor angiogenesis revisited: Regulators and clinical implications
- (2017) Roberto Ronca et al. MEDICINAL RESEARCH REVIEWS
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
- (2016) Weilan Ye DEVELOPMENTAL CELL
- Injectable hydrogel-based drug delivery systems for local cancer therapy
- (2016) Mohammad Norouzi et al. DRUG DISCOVERY TODAY
- Advances in immunotherapy for the treatment of glioblastoma
- (2016) Amanda Tivnan et al. JOURNAL OF NEURO-ONCOLOGY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Long-term delivery of protein therapeutics
- (2014) Ravi Vaishya et al. Expert Opinion on Drug Delivery
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis
- (2013) G. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epirubicin: Is it like doxorubicin in breast cancer? A clinical review
- (2012) Mustafa Khasraw et al. BREAST
- Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
- (2012) Farbod Shojaei CANCER LETTERS
- Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development
- (2011) Wei-Liang Sun et al. Autophagy
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
- (2010) K. Movahedi et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started